Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.

Abstract

This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800 mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500 mg twice daily, or trovafloxacin 200 mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia.

• Authors: C Carbon, D van Rensburg, L Hagberg, C Fogarty, G Tellier, M Rangaraju, R Nusrat
• Journal: Respiratory medicine (Respir Med) Vol. 100 Issue 4 Pg. 577-85 (Apr 2006) ISSN: 0954-6111 [Print] England
• PMID: 16376537 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Anti-Bacterial Agents
• Ketolides
• telithromycin

Topics

• Adolescent
• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• Clinical Trials, Phase IV as Topic
• Community-Acquired Infections (drug therapy, microbiology)
• Female
• Humans
• Ketolides (administration & dosage, therapeutic use)
• Male
• Meta-Analysis as Topic
• Middle Aged
• Multicenter Studies as Topic
• Pneumonia, Bacterial (drug therapy, microbiology)
• Randomized Controlled Trials as Topic
• Retrospective Studies